<!DOCTYPE html>
<html lang="zh-TW">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

    <title>2025 TMU-CWRU Symposium</title>

    <link href="https://fonts.googleapis.com/css2?family=DM+Sans:wght@400;500;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="static/css/style.css">
    <link rel="stylesheet" href="static/css/about.css">
    <link rel="stylesheet" href="static/css/photos.css">
</head>

<body>
    <header class="site-header">
        <div class="container">
            <div class="header-content">
                <div class="logo">
                    <a href="./">TMU-CWRU Symposium</a>
                </div>
                <nav class="main-nav">
                    <ul>
                        <li><a href="./">Home</a></li>
                        <li><a href="symposium.html">Symposium</a></li>
                    </ul>
                </nav>
                <div class="mobile-menu-btn">
                    <span></span>
                    <span></span>
                    <span></span>
                </div>
            </div>
        </div>
    </header>


    <main>
        <section class="profile-header">
            <div class="profile-content">
                <h2>Hsing-Jien Kung</h2>
                <div class="position">
                    <ul>
                        <li>Chair Professor,Taipei Medical University, Taipei, Taiwan</li>
                        <li>Distinguished Chair Professor for Research, National Taiwan University, Taipeiniversity</li>
                        <li>Distinguished Professor Emeritus, Department of Biochemistry and Molecular Medicine</li>
                        <li>University of California Davis School of Medicine, Sacramento, CA</li>
                        <li>President Emeritus, NHRI, Taiwan</li>
                    </ul>
                </div>
            </div>
            <div class="profile-image-hsing-jien-kung">
                <img src="static/images/hsing-jien-kung.jpg" alt="hsing-jien-kung">
            </div>
        </section>


        <section class="contact-info">
            <h3>EDUCATION/TRAINING</h3>
            
            <table class="address">
                <tr>
                    <th>INSTITUTION AND LOCATION</th>
                    <th>DEGREE</th>
                    <th>MM/YY</th>
                    <th>FIELD OF STUDY</th>
                </tr>
                <tr>
                    <td>National Taiwan University</td>
                    <td>BS</td>
                    <td>06/69</td>
                    <td>Chemistry</td>
                </tr>
                <tr>
                    <td>California Institute of Technology</td>
                    <td>PhD</td>
                    <td>12/75</td>
                    <td>Chemistry</td>
                </tr>
                <tr>
                    <td>University of California, San Francisco</td>
                    <td>Postdoc</td>
                    <td>03/78</td>
                    <td>Molecular Virology</td>
                </tr>
            </table>

        </section>

        <section class="honors">
            <section class="info-section">
                <h3>RESEARCH INTERESTS</h3>
                <div class="info-content">
                    <p>
                        My lab has contributed to our understanding of oncogenes, signal transduction, viral oncogenesis, cancer metabolism and
                        epigenetics. We were credited for the original discovery of dimer structure of retrovirus genome (Cell, 1976), erbB/EGFR
                        as a target gene for retroviral insertion (Cell, 1983, 1986, 1993, Nature, 1981), establishing this locus as a
                        protooncogene, initial cloning of human c-src gene and demonstrating oncogenecity of v-src DNA (PNAS, 1983), and the
                        discoveries of several tyrosine kinase- and viral oncogenes (Nature Cell Biol, 2002, PNAS, 1992, 1998). In the area of
                        prostate cancer, his lab contributed to: the first tyrosine kinase profile (PNAS, 1996), the discovery of truncated AR
                        in CWR22Rv1 (Cancer Res, 2002, 2009), the discovery of IL6 and erbB crosstalk (Nature, 1998), the demonstration of
                        IL6-induced neuroendocrine differentiation (PNAS, 1998), the identification of the first Long-noncoding RNA coactivator
                        of myc (PNAS, 2014) and of HIF-1a (Nat Comm, 2017), the definition of the origin of human retrovirus XMRV (dispelling
                        its involvement in prostate cancer) (Science, 2012), the first demonstration of tumor specific killing of prostate
                        cancer by arginine-deprivation (Cancer Res, 2009), the discovery of chromatin-autophagy (PNAS, 2014), histone
                        demethylase KDM4A as E2F coactivator and tumor metabolism (Cell Reports, 2016), arginine deprivation leads to cGAS-STING
                        activation (Theranostics, 2021) and arginine as an epigenetic regulator of mitochondria (Nature Communication, 2021,
                        Cell Reports, 2023).<br><br>
                        My current interests are :1) Metabolic modulation of ferroptosis to overcome prostate cancer drug resistance. 2) Super-enhancers involved in
                        prostate cancer progression. 3) RNA complexes associated with hypoxia and hybrid EMT
                        responses. 4) Exosomal RNAs involved in muscle aging and sarcopenia.
                    </p>
                </div>
            </section>
        </section>

        <section class="publications">
            <section class="info-section">
                <h3>Selected Recent Publications</h3>
                <div class="info-content">
                    <h4>Original Paper:</h4>
                    <ul class="publications-list">
                        <li>Rogers LR, Ostrom QT, Scroer J, Vengoechea J, Li L, Gerson S, Nock CJ, Machtay M, Selman W,
                            Lo S, Sloan
                            AE, Barnholtz-Sloan JS. Association of metabolic syndrome with glioblastoma: a retrospective
                            cohort
                            study and review. Neurooncol Pract 2020 Mar 31;7(5):541-548. Doi:1031093/nop/npaa011.
                            ECollection Oct.
                            PMID: 33014395</li>
                        <li>Chamoun K, Firoozmand A, Caimi P, Fu P, Cao S, Otegbeye F, Metheny L, Patel S, Gerson SL,
                            Boughan K, de
                            Lima M, Malek E. Socioeconimic factors and survival of multiple myeloma patients. Cancers
                            (Basel). 2021
                            Feb 3;13(4):590. Doi: 10.3390/cancers 13040590. PMID: 3354626</li>
                        <li>Gerson SL, Shaw K, Harrison LB, Holcombe RF, Hutchins L, Lee CB, Loebrer PJ, Mulkerin D,
                            Purcell WT,
                            Teston L, Weiner LM, Weiner GJ. Status of Cancer Care at Network Sites of the Nation's
                            Academic Cancer
                            Centers. Natl Compr Canc Netw 2021 Mar 11:1-7. Coi: 10.6004/jnccn 2020.7656. Online ahead of
                            print PMIC:
                            33706258</li>
                        <li>Smith JN, Dawson DM, Christo KF, Jogasuria AP, Cameron MJ, Antezak MI, Ready JM, Gerson SL,
                            Markowitz
                            SD, Desai AB. 15-PGDH inhibition activates the splenic niche to promote hematopoietic
                            regeneration. JCI
                            Insight 2021 Mar 22:6(6):e143658. Doi: 10.1172/jci.insight 143658. PMID: 33600377</li>
                        <li>Nguyen MT, Moiani D, Ahmed Z, Arvai AS, Namioshi S, Shin DS, Fedorov Y, Selvik EJ, Jones DE,
                            Pink J, Yan
                            Y, Vaverty DJ, Nagel ZD, Tainer JA, Gerson SL. An effective human eracil-DNA glycosylase
                            inhibitor
                            targets the open pre-catalytic active site conformation. Prog Biophys Mol Biol. 2021 Aug;
                            163:143-159.
                            Doi: 10.1016/j.pbiomolbio.2021.02.004. Epub 2021 Mar 3 PMID: 33675849</li>
                        <li>Biswas T, Dowlati A, Konos CA, Pink JJ, Oleinick NL, Malik S, Fu P, Cao S, Bruno DS, Bajor
                            DL, Patel M,
                            Gerson SL, Machtay M. Adding base-excision repair inhibitor TRC102 to standard
                            pemetrexed-platinum-radiation in patients with advanced nonsquamous non-small cell lung
                            cancer: results
                            of a Phase I Trial. Clin Cancer Res 2022 Feb 15;28(4):646-652. Doi:
                            10.1158/1078-0432.CCR-21-2025. PMID:
                            34740922</li>
                        <li>Jajosky AN, Mitchell AL, Akgul M, Shetty S, Yoest JM, Gerson SL, Sadri N, Oduro KA Jr.
                            Identification of
                            a cancer-predisposing germline POT1 p.lle49Metfs*7 variant by targeted sequencing of a
                            splenic marginal
                            zone lymphoma. Genes (Basel). 2022 Mar 26;13(4):591. Doi: 10.3390/genes13040591. PMID:
                            35456397</li>
                        <li>Ho WJ, Smith JNP, Park YS, Hadiono M, Christo K, Jogasuri A, Zhang Y, Broncano AV, Kasturi
                            I, Dawson DM,
                            Gerson SL, Markowitz SD, Desai AB. 15-PGDH regulates hematopoietic and gastrointestinal
                            fitness during
                            aging. PLoS One. 2022 May 19;17(5):e0268787. Doi: 10.1371/journal pone.0268787. eCollection
                            2022. PMID:
                            35587945</li>
                        <li>Baluku JB, Namiiro S, Namanda B, Katusabe S, Namusoke D, Nkonge R, Okecha T, Nassaazi C,
                            Niyonzima N,
                            Bogere N, Nuwagira E, Nabwana M, Ssekamatte P, Andia-Biraro I, Worodria W, Salata R,
                            Mfinanga S, Gerson
                            S, Kirenga B. Mycobacterium tuberculosis infection and cytogenetic abnormalities among
                            people with HIV.
                            Mutat Res Genet Toxicol Environ Mutagen. 2023 May-Jun;888:503640. doi:
                            10.1016/j.mrgentox.2023.503640.
                            PMID: 37188437</li>
                        <li>Qing Y, Chan R, Fu P, Cullen J, Miron A, Jacobson JM, Pink J, Gerson SL. Impact of age,
                            antiretroviral
                            therapy, and cancer on epigenetic aging in people living with HIV. Cancer Med. 2023
                            May;12(9):11010-11019. doi: 10.1002/cam4.5809. Epub 2023 Mar 23.PMID: 36951656</li>
                        <li>Baluku JB, Namiiro S, Namanda B, Nabwana M, Andia-Biraro, IA, Worodria W, Salata R, Mfinanga
                            S, Gerson
                            S, Krenga B. Neutrophil-lymphocyte and platelet-lymphocyte ratios in distinguishing lung
                            cancer in
                            people with HIV. Hindawi Disease Markers, vol. 2024 Article ID 8822024, 6 pages</li>
                    </ul>
                    <p><a href="https://doi.org/10.1155/2024/8822024">https://doi.org/10.1155/2024/8822024</a>
                </div>
            </section>
        </section>

    </main>
    <script src="static/js/main.js"></script>
</body>

</html>